Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
1. FDA warns Hims & Hers over misleading drug promotion claims. 2. Hims marketed non-FDA-approved semaglutide products, facing regulatory scrutiny. 3. Risk exposure for ETFs with Hims may impact their performance. 4. Eli Lilly and Novo Nordisk are under similar scrutiny, impacting sector sentiment. 5. Market leaders may still perform well despite regulatory concerns.